Share Price and Basic Stock Data
Last Updated: January 9, 2026, 5:39 am
| PEG Ratio | 1.43 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alpa Laboratories Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹77.5 and a market capitalization of ₹161 Cr. The company has experienced fluctuations in quarterly sales, with a notable increase from ₹13.54 Cr in September 2022 to ₹32.39 Cr in September 2023. However, sales dipped to ₹25.43 Cr in June 2023 before recovering again. Annual sales figures indicate a gradual growth trajectory, rising from ₹56 Cr in March 2014 to ₹110 Cr in the trailing twelve months (TTM) ending March 2025. The latest reported sales of ₹110 Cr for FY 2025 marks a stable performance compared to ₹109 Cr in FY 2024. This consistent revenue generation reflects Alpa Laboratories’ ability to navigate market challenges effectively, although the pharmaceutical industry typically expects higher growth rates, indicating a potential area for improvement.
Profitability and Efficiency Metrics
Alpa Laboratories reported a P/E ratio of 8.55, suggesting that the stock may be undervalued compared to industry peers. The company’s net profit stood at ₹19 Cr, translating to an EPS of ₹9.34 for FY 2025. The operating profit margin (OPM) was notably low at -11.20% for the last reported quarter, indicating challenges in managing operational costs effectively. The return on equity (ROE) was 11.5%, while the return on capital employed (ROCE) improved to 15.0%, both demonstrating reasonable efficiency in generating returns for shareholders. The interest coverage ratio (ICR) stood impressively at 121.23x, highlighting the company’s capacity to cover interest expenses. However, the negative OPM suggests that cost control measures must be enhanced to improve overall profitability in line with sector averages.
Balance Sheet Strength and Financial Ratios
Alpa Laboratories maintains a conservative capital structure, with total borrowings recorded at just ₹2 Cr, showcasing minimal debt reliance. The reserves have steadily increased from ₹67 Cr in March 2014 to ₹173 Cr in September 2025, reflecting a robust accumulation of equity capital. The company’s current ratio stood at 4.12, indicating strong liquidity, while the quick ratio of 3.74 further reinforces its short-term financial health. The price-to-book value (P/BV) ratio is at 1.28x, slightly above the sector norm, suggesting that the stock is valued at a premium relative to its book value. However, the cash conversion cycle (CCC) of 150 days indicates inefficiencies in working capital management, which could be improved to enhance cash flow and operational efficiency.
Shareholding Pattern and Investor Confidence
The shareholding structure of Alpa Laboratories reveals a strong promoter backing, holding 57.29% of the equity. This substantial ownership provides confidence to investors regarding management’s commitment to long-term growth. However, foreign institutional investors (FIIs) hold only 0.35% of the shares, while domestic institutional investors (DIIs) hold none, reflecting a lack of institutional interest. The public shareholding stood at 42.36%, with a total of 18,542 shareholders, indicating a relatively broad retail investor base. The gradual decline in total shareholders from 19,094 in December 2022 to 18,542 in September 2025 may raise concerns about investor confidence, potentially linked to the company’s inconsistent quarterly performance. Enhancing transparency and operational performance could attract more institutional investment.
Outlook, Risks, and Final Insight
The outlook for Alpa Laboratories is cautiously optimistic, given its strong liquidity position and minimal debt. However, the company faces several risks, including operational inefficiencies reflected in the negative OPM and high CCC, which could hinder profitability if not addressed. Additionally, the lack of institutional investment may limit the stock’s upward potential. Strengths include a solid promoter holding and a robust reserve base, which could provide a buffer during market fluctuations. To enhance its market position, Alpa Laboratories must focus on improving operational efficiencies and increasing its market share in the competitive pharmaceutical sector. If the company successfully implements these strategies, it could leverage its existing strengths to achieve sustainable growth and improved investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 208/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,404 Cr. | 404 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,548.25 Cr | 1,144.26 | 53.56 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.54 | 27.31 | 29.16 | 25.43 | 32.39 | 27.31 | 23.61 | 21.44 | 24.94 | 26.15 | 39.11 | 19.11 | 25.63 |
| Expenses | 19.28 | 24.68 | 19.90 | 26.58 | 29.07 | 24.85 | 20.10 | 20.90 | 21.67 | 25.41 | 39.47 | 18.69 | 28.50 |
| Operating Profit | -5.74 | 2.63 | 9.26 | -1.15 | 3.32 | 2.46 | 3.51 | 0.54 | 3.27 | 0.74 | -0.36 | 0.42 | -2.87 |
| OPM % | -42.39% | 9.63% | 31.76% | -4.52% | 10.25% | 9.01% | 14.87% | 2.52% | 13.11% | 2.83% | -0.92% | 2.20% | -11.20% |
| Other Income | 6.38 | 2.69 | -0.76 | 4.47 | 2.95 | 3.55 | 3.97 | 5.18 | 6.91 | 8.80 | 3.24 | 11.96 | 3.69 |
| Interest | 0.08 | 0.07 | 0.04 | 0.02 | 0.04 | 0.03 | 0.30 | 0.05 | 0.06 | 0.10 | 0.05 | 0.05 | 0.05 |
| Depreciation | 0.36 | 0.10 | 0.53 | 0.28 | 0.49 | 0.66 | 0.52 | 0.54 | 0.53 | 0.55 | 0.58 | 0.55 | 0.67 |
| Profit before tax | 0.20 | 5.15 | 7.93 | 3.02 | 5.74 | 5.32 | 6.66 | 5.13 | 9.59 | 8.89 | 2.25 | 11.78 | 0.10 |
| Tax % | 0.00% | 0.00% | 41.74% | 0.00% | 0.00% | 14.85% | 46.70% | 0.00% | 20.44% | 0.00% | 186.67% | 0.00% | 0.00% |
| Net Profit | 0.20 | 5.14 | 4.62 | 3.03 | 5.74 | 4.53 | 3.55 | 5.12 | 7.63 | 8.89 | -1.95 | 11.78 | 0.10 |
| EPS in Rs | 0.10 | 2.44 | 2.20 | 1.44 | 2.73 | 2.15 | 1.69 | 2.43 | 3.63 | 4.23 | -0.93 | 5.60 | 0.05 |
Last Updated: January 2, 2026, 1:04 pm
Below is a detailed analysis of the quarterly data for Alpa Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 25.63 Cr.. The value appears strong and on an upward trend. It has increased from 19.11 Cr. (Jun 2025) to 25.63 Cr., marking an increase of 6.52 Cr..
- For Expenses, as of Sep 2025, the value is 28.50 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.69 Cr. (Jun 2025) to 28.50 Cr., marking an increase of 9.81 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.87 Cr.. The value appears to be declining and may need further review. It has decreased from 0.42 Cr. (Jun 2025) to -2.87 Cr., marking a decrease of 3.29 Cr..
- For OPM %, as of Sep 2025, the value is -11.20%. The value appears to be declining and may need further review. It has decreased from 2.20% (Jun 2025) to -11.20%, marking a decrease of 13.40%.
- For Other Income, as of Sep 2025, the value is 3.69 Cr.. The value appears to be declining and may need further review. It has decreased from 11.96 Cr. (Jun 2025) to 3.69 Cr., marking a decrease of 8.27 Cr..
- For Interest, as of Sep 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.05 Cr..
- For Depreciation, as of Sep 2025, the value is 0.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.55 Cr. (Jun 2025) to 0.67 Cr., marking an increase of 0.12 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 11.78 Cr. (Jun 2025) to 0.10 Cr., marking a decrease of 11.68 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 11.78 Cr. (Jun 2025) to 0.10 Cr., marking a decrease of 11.68 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.05. The value appears to be declining and may need further review. It has decreased from 5.60 (Jun 2025) to 0.05, marking a decrease of 5.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 110 |
| Expenses | 51 | 54 | 47 | 56 | 57 | 76 | 79 | 90 | 101 | 85 | 100 | 105 | 112 |
| Operating Profit | 6 | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | -2 |
| OPM % | 10% | 6% | 13% | 11% | 7% | 2% | 7% | 8% | 10% | 9% | 8% | 5% | -2% |
| Other Income | 1 | 2 | 6 | 4 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 23 | 28 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Profit before tax | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 21 | 26 | 23 |
| Tax % | 4% | -48% | 27% | 34% | 27% | 36% | 20% | 33% | 28% | 21% | 19% | 24% | |
| Net Profit | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 17 | 20 | 19 |
| EPS in Rs | -2.45 | -0.67 | 3.68 | 2.85 | 2.27 | 1.40 | 1.94 | 3.45 | 6.72 | 6.00 | 7.98 | 9.35 | 8.95 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 80.00% | 900.00% | -25.00% | -16.67% | -40.00% | 33.33% | 75.00% | 100.00% | -7.14% | 30.77% | 17.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | 820.00% | -925.00% | 8.33% | -23.33% | 73.33% | 41.67% | 25.00% | -107.14% | 37.91% | -13.12% |
Alpa Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 55% |
| 5 Years: | 30% |
| 3 Years: | 36% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 27% |
| 3 Years: | 15% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| Last Year: | 11% |
Last Updated: September 4, 2025, 11:00 pm
Balance Sheet
Last Updated: January 7, 2026, 3:21 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 124 | 141 | 161 | 173 |
| Borrowings | 23 | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 3 | 5 | 0 | 2 |
| Other Liabilities | 15 | 13 | 27 | 20 | 17 | 21 | 21 | 33 | 28 | 30 | 25 | 51 | 52 |
| Total Liabilities | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
| Fixed Assets | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 11 | 21 | 21 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 | 109 | 129 | 157 |
| Other Assets | 54 | 113 | 118 | 100 | 79 | 64 | 56 | 80 | 70 | 81 | 72 | 83 | 70 |
| Total Assets | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
Below is a detailed analysis of the balance sheet data for Alpa Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 173.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2025) to 173.00 Cr., marking an increase of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 52.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 248.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 157.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 28.00 Cr..
- For Other Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 13.00 Cr..
- For Total Assets, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
Notably, the Reserves (173.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -26.00 | -17.00 | -4.00 | -2.00 | -1.00 | 6.00 | 8.00 | 5.00 | 5.00 | 4.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 156 | 234 | 169 | 151 | 141 | 105 | 133 | 124 | 186 | 138 | 155 |
| Inventory Days | 148 | 76 | 196 | 131 | 140 | 105 | 90 | 102 | 81 | 84 | 73 | 92 |
| Days Payable | 121 | 91 | 244 | 140 | 130 | 99 | 98 | 152 | 78 | 100 | 63 | 97 |
| Cash Conversion Cycle | 157 | 141 | 187 | 160 | 161 | 148 | 97 | 83 | 127 | 170 | 149 | 150 |
| Working Capital Days | 65 | -4 | 224 | 197 | 204 | 189 | 121 | 137 | 124 | 150 | 132 | 108 |
| ROCE % | -3% | 0% | 10% | 11% | 7% | 4% | 7% | 7% | 9% | 11% | 14% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Diluted EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Cash EPS (Rs.) | 10.32 | 8.90 | 6.61 | 7.48 | 4.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Revenue From Operations / Share (Rs.) | 53.45 | 51.68 | 44.18 | 53.36 | 46.36 |
| PBDIT / Share (Rs.) | 13.36 | 10.93 | 8.29 | 10.19 | 5.75 |
| PBIT / Share (Rs.) | 12.31 | 10.00 | 7.66 | 9.40 | 5.16 |
| PBT / Share (Rs.) | 12.20 | 9.83 | 7.55 | 9.30 | 5.13 |
| Net Profit / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| NP After MI And SOA / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| PBDIT Margin (%) | 24.98 | 21.14 | 18.76 | 19.09 | 12.39 |
| PBIT Margin (%) | 23.03 | 19.35 | 17.33 | 17.61 | 11.13 |
| PBT Margin (%) | 22.82 | 19.01 | 17.09 | 17.42 | 11.05 |
| Net Profit Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| NP After MI And SOA Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| Return on Networth / Equity (%) | 11.37 | 11.04 | 9.34 | 11.57 | 6.73 |
| Return on Capital Employeed (%) | 14.72 | 13.63 | 11.90 | 15.97 | 10.07 |
| Return On Assets (%) | 8.76 | 9.19 | 7.52 | 9.07 | 5.16 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.03 | 0.01 | 0.04 | 0.00 |
| Asset Turnover Ratio (%) | 0.55 | 0.62 | 0.57 | 0.73 | 0.71 |
| Current Ratio (X) | 4.12 | 5.74 | 4.67 | 4.43 | 3.73 |
| Quick Ratio (X) | 3.74 | 5.25 | 4.28 | 3.93 | 3.22 |
| Inventory Turnover Ratio (X) | 7.18 | 8.27 | 3.73 | 3.96 | 3.73 |
| Interest Coverage Ratio (X) | 121.23 | 64.02 | 78.01 | 97.84 | 155.24 |
| Interest Coverage Ratio (Post Tax) (X) | 85.14 | 47.71 | 57.27 | 65.32 | 94.03 |
| Enterprise Value (Cr.) | 216.89 | 179.04 | 106.65 | 149.57 | 65.56 |
| EV / Net Operating Revenue (X) | 1.93 | 1.65 | 1.15 | 1.33 | 0.67 |
| EV / EBITDA (X) | 7.72 | 7.79 | 6.11 | 6.98 | 5.42 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| Price / BV (X) | 1.28 | 1.16 | 0.84 | 1.20 | 0.70 |
| Price / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| EarningsYield | 0.08 | 0.09 | 0.11 | 0.09 | 0.09 |
After reviewing the key financial ratios for Alpa Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.32. This value is within the healthy range. It has increased from 8.90 (Mar 24) to 10.32, marking an increase of 1.42.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 53.45. It has increased from 51.68 (Mar 24) to 53.45, marking an increase of 1.77.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.36. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 13.36, marking an increase of 2.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.31. This value is within the healthy range. It has increased from 10.00 (Mar 24) to 12.31, marking an increase of 2.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.20. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 12.20, marking an increase of 2.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 24.98. This value is within the healthy range. It has increased from 21.14 (Mar 24) to 24.98, marking an increase of 3.84.
- For PBIT Margin (%), as of Mar 25, the value is 23.03. This value exceeds the healthy maximum of 20. It has increased from 19.35 (Mar 24) to 23.03, marking an increase of 3.68.
- For PBT Margin (%), as of Mar 25, the value is 22.82. This value is within the healthy range. It has increased from 19.01 (Mar 24) to 22.82, marking an increase of 3.81.
- For Net Profit Margin (%), as of Mar 25, the value is 17.34. This value exceeds the healthy maximum of 10. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.34. This value is within the healthy range. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.37. This value is below the healthy minimum of 15. It has increased from 11.04 (Mar 24) to 11.37, marking an increase of 0.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.72. This value is within the healthy range. It has increased from 13.63 (Mar 24) to 14.72, marking an increase of 1.09.
- For Return On Assets (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 8.76, marking a decrease of 0.43.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.55. It has decreased from 0.62 (Mar 24) to 0.55, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has decreased from 5.74 (Mar 24) to 4.12, marking a decrease of 1.62.
- For Quick Ratio (X), as of Mar 25, the value is 3.74. This value exceeds the healthy maximum of 2. It has decreased from 5.25 (Mar 24) to 3.74, marking a decrease of 1.51.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.18. This value is within the healthy range. It has decreased from 8.27 (Mar 24) to 7.18, marking a decrease of 1.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 121.23. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 121.23, marking an increase of 57.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 85.14. This value is within the healthy range. It has increased from 47.71 (Mar 24) to 85.14, marking an increase of 37.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 216.89. It has increased from 179.04 (Mar 24) to 216.89, marking an increase of 37.85.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 1.93, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 7.79 (Mar 24) to 7.72, marking a decrease of 0.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For Price / BV (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 1.28, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 24) to 0.08, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alpa Laboratories Ltd:
- Net Profit Margin: 17.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.72% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.37% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 85.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 8.45 (Industry average Stock P/E: 53.56)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 33/2, Pigdamber, A.B.Road, Rau, Indore Madhya Pradesh 453446 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra Singh Chawla | Chairman |
| Mr. Paresh Chawla | Managing Director |
| Mr. Pravin Shah | Director |
| Mr. Vitthal Kothana | Director |
| Mr. Shitul Shah | Director |
| Mrs. Jyoti Jain | Independent Director |
| Mr. Sanket Baheti | Independent Director |
| Mr. Pratik Shah | Independent Director |
| Mrs. Pratibha Lunawat | Independent Director |
| Mr. Sunil Kumar Valecha | Independent Director |
FAQ
What is the intrinsic value of Alpa Laboratories Ltd?
Alpa Laboratories Ltd's intrinsic value (as of 09 January 2026) is ₹72.95 which is 3.51% lower the current market price of ₹75.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹159 Cr. market cap, FY2025-2026 high/low of ₹137/73.6, reserves of ₹173 Cr, and liabilities of ₹248 Cr.
What is the Market Cap of Alpa Laboratories Ltd?
The Market Cap of Alpa Laboratories Ltd is 159 Cr..
What is the current Stock Price of Alpa Laboratories Ltd as on 09 January 2026?
The current stock price of Alpa Laboratories Ltd as on 09 January 2026 is ₹75.6.
What is the High / Low of Alpa Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alpa Laboratories Ltd stocks is ₹137/73.6.
What is the Stock P/E of Alpa Laboratories Ltd?
The Stock P/E of Alpa Laboratories Ltd is 8.45.
What is the Book Value of Alpa Laboratories Ltd?
The Book Value of Alpa Laboratories Ltd is 92.0.
What is the Dividend Yield of Alpa Laboratories Ltd?
The Dividend Yield of Alpa Laboratories Ltd is 0.00 %.
What is the ROCE of Alpa Laboratories Ltd?
The ROCE of Alpa Laboratories Ltd is 15.0 %.
What is the ROE of Alpa Laboratories Ltd?
The ROE of Alpa Laboratories Ltd is 11.5 %.
What is the Face Value of Alpa Laboratories Ltd?
The Face Value of Alpa Laboratories Ltd is 10.0.